Skip to main content
Advanced Biomed Inc. logo

Advanced Biomed Inc. — Investor Relations & Filings

Ticker · ADVB ISIN · US00752P1049 US Professional, scientific and technical activities
Open in API
Filings indexed 85 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country US United States of America
Listing US ADVB

About Advanced Biomed Inc.

http://www.advanbiomed.com/

Advanced Biomed Inc. is a company specializing in the research, development, and commercialization of advanced diagnostic systems for precision oncology. The company focuses on developing proprietary microfluidic biochip technologies that integrate semiconductor and biotechnology principles. Its platform provides assay products and services that cover the full spectrum of cancer care, including early screening, detection, diagnosis, staging, and treatment selection. A key technology involves diagnostic devices that capture circulating tumor cells through physical trapping, offering an alternative to traditional antibody-based methods. The company aims to provide rapid and affordable solutions to improve patient outcomes.

Recent filings

Filing Released Lang Actions
QUARTERLY REPORT
Interim / Quarterly Report Q3 2026
2026-05-15 English
8-K - Advanced Biomed Inc. (0001941029) (Filer)
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content includes the completion of an acquisition (Item 2.01), unregistered sales of equity securities (Item 3.02), and significant changes in management including the departure of the CEO and appointment of a new CEO (Item 5.02). The document also references employment and termination agreements as exhibits. The Form 8-K is a regulatory filing used to disclose material corporate events promptly and is not a full annual or quarterly report, nor an earnings release or proxy statement. The presence of management changes and acquisition completion announcements within a Form 8-K aligns with the Regulatory Filings (RNS) category, which is the fallback for miscellaneous SEC filings that do not fit other specific categories. Therefore, the appropriate classification is Regulatory Filings (RNS).
2026-05-01 English
8-K - Advanced Biomed Inc. (0001941029) (Filer)
Regulatory Filings
2026-04-14 English
8-K - Advanced Biomed Inc. (0001941029) (Filer)
M&A Activity Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement for the acquisition of another company, including details of the share purchase agreement and conditions for closing. It also references the filing of the agreement as an exhibit. This type of filing is typically categorized under M&A Activity (TAR) because it announces a merger or acquisition transaction. The document is not a full annual or quarterly report, nor is it an earnings release or a proxy statement. It is not a regulatory filing of miscellaneous nature but a specific transaction announcement. Therefore, the correct classification is M&A Activity (TAR). The confidence in this classification is high given the clear description of the acquisition agreement and the Form 8-K context.
2026-04-03 English
8-K - ADVANCED BIOMED INC. (0001941029) (Filer)
Share Issue/Capital Change Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content specifically details a reverse stock split (1-for-20) of the company's common stock, including the filing of a Certificate of Amendment and the effective date of the change. It also references a press release about the reverse stock split. This type of filing is a capital structure change announcement, which fits the category of Share Issue/Capital Change (SHA). The document is not a full financial report, earnings release, or management discussion, but a regulatory announcement of a capital change event. The length and detail confirm it is the actual filing, not just a brief announcement or certification. Therefore, the correct classification is SHA with high confidence.
2026-02-26 English
10-Q Filing
Interim / Quarterly Report Q2 2026
2026-02-13 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.